



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066
Email: info@smspharma.com, www.smspharma.com

Date: 03rd August, 2024

To
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001.

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Intimation of Investor's Conference Call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing here with invitation for Investor's Conference Call, scheduled to be held on Wednesday, 07th August, 2024 at 11:00 AM, IST, to discuss the Company's financial performance for the quarter ended 30th June, 2024.

Please take into your records

Thanking you

Yours Faithfully

For SMS Pharmaceuticals Limited

Thirumalesh Tumma
Company Secretary



Hyderabad, August 5, 2024: SMS Pharmaceuticals Ltd, a diversified and integrated pharmaceutical company specialising in APIs and intermediates, will announce its results for the first quarter ended June 30, 2024, on Monday, August 05, 2024.

The results will also be available on the Company's website, www.smspharma.com. The company will hold an earnings conference on Wednesday, August 07, at 11.00 am IST, where senior management will discuss its results and performance.

SMS Pharmaceuticals Q1 FY 2025 Earnings Call on Wednesday, August 07, 2024, at 11.00 am (IST)

Conference Dial-In Information:

Diamond Pass: Please [click here](#) to please pre-register for the call

Primary Number:	+91 22 6280 1260
	+91 22 7115 8197
Toll Free Number:	Hongkong – 800964448
	Singapore – 8001012045
	UK – 08081011573
	US – 18667462133

For any further information, please contact:

Investor Relations:

EQSPONENT Partners LLP
Aditya Dutta
M. +91 98187 39589